Sargent Investment Group, LLC Chroma Dex Corp. Transaction History

Sargent Investment Group, LLC

$702 Million
Q2 2025

A detailed history of Sargent Investment Group, LLC transactions in Chroma Dex Corp. stock. As of the latest transaction made, Sargent Investment Group, LLC holds 50,000 shares of CDXC stock, worth $307,000. This represents 0.04% of its overall portfolio holdings.

Number of Shares

50,000

Previous 50,000 -0.0%

Holding current value

$307,000

Previous $345,000 11.01%

% of portfolio

0.04%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	BUY	$3.25 - $7.72 $162,500 - $386,000	50,000 New	50,000 $265,000
Q4 2021 Feb 11, 2022	SELL	$3.74 - $6.7 $18,700 - $33,500	-5,000 Reduced 23.81%	16,000 $60,000
Q3 2021 Nov 12, 2021	BUY	$6.05 - $10.41 $6,050 - $10,410	1,000 Added 5.0%	21,000 $132,000
Q4 2020 Feb 10, 2021	SELL	$3.93 - $5.5 $19,650 - $27,500	-5,000 Reduced 20.0%	20,000 $96,000
Q3 2020 Nov 12, 2020	BUY	$4.01 - $5.56 $52,130 - $72,280	13,000 Added 108.33%	25,000 $100,000
Q2 2020 Aug 11, 2020	SELL	$3.0 - $5.52 $246,000 - $452,639	-82,000 Reduced 87.23%	12,000 $54,000
Q1 2020 May 12, 2020	BUY	$2.54 - $4.75 $208,280 - $389,500	82,000 Added 683.33%	94,000 $306,000
Q4 2019 Jan 30, 2020	BUY	$2.83 - $4.61 $33,960 - $55,320	12,000 New	12,000 $52,000
Q3 2019 Oct 29, 2019	SELL	$3.83 - $4.72 $390,660 - $481,440	-102,000 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$3.71 - $4.83 $5,565 - $7,245	-1,500 Reduced 1.45%	102,000 $474,000
Q4 2018 Feb 12, 2019	BUY	$2.8 - $4.22 $289,800 - $436,770	103,500 New	103,500 $355,000

Others Institutions Holding CDXC

# of Institutions

171

Shares Held

28.3M

Call Options Held

143K

Put Options Held

189K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $420M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.

Account

Sargent Investment Group, LLC Chroma Dex Corp. Transaction History